Allogeneic stem cell transplantation for patients with high-risk myelodysplastic syndrome

Journal of the Formosan Medical Association

Volumn 98, Issue 3, 1999, Pages 157-164

  Hsu, Chiun ^a,b   Lin, Ming Tseh ^a,b   Tang, Jih Luh ^a,b   Tien, Hwei Fang ^b   Wang, Chiu Hwa ^b,c   Chen, Yao Chang ^a,b,c  

^a Bone Marrow Transplantation Unit   (Taiwan)

^b Department of Oncology ^*  (Taiwan)

^c NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Allogeneic bone marrow transplantation; Graft versus host disease; Myelodysplastic syndrome; Stem cell transplantation

Indexed keywords

CYCLOPHOSPHAMIDE; CYTARABINE; METHOTREXATE;

ADULT; ALLOGENEIC RESTRICTION; ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; BLOOD TRANSFUSION; CLINICAL ARTICLE; CLINICAL FEATURE; DISEASE COURSE; FEMALE; GRAFT VERSUS HOST REACTION; HLA MATCHING; HUMAN; HUMAN CELL; MALE; MYELODYSPLASTIC SYNDROME; PROGNOSIS; RECURRENT INFECTION; REMISSION; SCORING SYSTEM; STEM CELL TRANSPLANTATION; WHOLE BODY RADIATION;

ADULT; DISEASE-FREE SURVIVAL; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; SURVIVAL RATE; TAIWAN; TRANSPLANTATION CONDITIONING;

EID: 0033014518     PISSN: 09296646     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Bennet JM, Catovsky D, Daniel MT, et al: Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 1982;51:189-99.
2. Greenberg P, Cox C, LeBeau M, et al: International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997;89:2079-88.
3. Hirst WJR, Mufti GJ: Clinical annotation: management of myelodysplastic syndrome. Br J Haematol 1993:84:191-6.
4. Fenaux P, Morel P, Rose C, et al: Prognostic factors in adult de novo myelodysplastic syndromes treated by intensive chemotherapy. Br J Haematol 1991;77:497-501.
5. Gassmann W, Schmitz N, Loeffler H, et al: Intensive chemotherapy and bone marrow transplantation for myelodysplastic syndromes. Semin Hematol 1996;33: 196-205.
6. Thomas ED, Storb R, Clift RA, et al: Bone marrow transplantation. N Engl J Med 1975;292:895-902.
7. Kaplan EL, Meier P: Nonparametric estimation from incomplete observation. J Am Stat Assoc 1958;53:457.
8. Maschek H, Georgii A, Kaloutsi V, et al: Myelofibrosis in primary myelodysplastic syndromes: a retrospective study of 352 patients. Eur J Haematol 1992;48:208-14.
9. Longo DL: Approach to the patient with cancer. In: Fauci AS, Braunwald E, Isselbacher KJ, et al, eds. Harrison's Principles of Internal Medicine. 14th ed. New York: McGraw-Hill, 1998:493-9.
10. Tang JL, Lin MT, Liu MC, et al: Successful reinduction of remission with low-dose Ara-c in a patient with myelodysplastic syndrome relapsed after allogeneic bone marrow transplantation: restoration of donor hematopoiesis detected by amplification of minisatellite genes. Transplant Proc 1992;24:1522-3.
11. Tien HF, Wang CH, Chuang SM, et al: Cytogenetic studies, ras mutation, and clinical characteristics in primary myelodysplastic syndrome. A study on 68 Chinese patients in Taiwan. Cancer Genet Cytogenet 1994;74:40-9.
12. Runde V, de Witte T, Arnold R, et al: Bone marrow transplantation from HLA-identical siblings as first-line treatment in patients with myelodysplastic syndrome: early transplantation is associated with improved outcome. Bone Marrow Transplant 1998;21:255-61.
13. Anderson JE, Appelbaum FR, Fisher LD, et al: Allogeneic bone marrow transplantation for 93 patients with myelodysplastic syndrome. Blood 1993;82:677-81.
14. Anderson JE, Thomas ED: The Seattle experience with bone marrow transplantation (BMT) for myelodysplasia (MDS). Leuk Res 1997;21 (Suppl 1):S51.
15. Sutton L, Chastang C, Ribaud P, et al: Factors influencing outcome in de novo myelodysplastic syndrome treated by allogeneic bone marrow transplantation: a long-term study of 71 patients. Blood 1996;88:358-65.
16. Ratanatharathorn V, Karanes C, Uberti J, et al: Busulfan-based regimens and allogeneic bone marrow transplantation in patients with myelodysplastic syndromes. Blood 1993:81:2194-9.
17. Longmore G, Guinan EC, Weinstein HJ, et al: Bone marrow transplantation for myelodysplasia and secondary acute non-lymphoblastic leukemia. J Clin Oncol 1990; 8:1707-14.
18. Nevill TJ, Shepherd JD, Recce DE, et al: Treatment of myelodysplastic syndromes with busulfan-cyclophosphamide conditioning followed by allogeneic BMT. Bone Marrow Transplant 1992:10:445-50.
19. Nash RA, Pepe MS, Storb R, et al: Acute graft-versus-host disease: analysis of risk factors after allogeneic marrow transplantation and prophylaxis with cyclosporin and methotrexate. Blood 1992;80:1838-45.
20. Clift RA, Buckner CD, Appelbaum FA, et al: Allogeneic marrow transplantation in patients with chronic myeloid leukemia in the chronic phase. A randomized trial of two irradiation regimens. Blood 1991:77:1660-5.
21. Deeg HJ, Spitzer TR, Gottler-Fox M, et al: Conditioning-related toxicity and acute graft-versus-host disease in patients given methotrexate/cyclosporin prophylaxis. Bone Marrow Transplant 1991:7:193-8.
22. Chen YC, Lin KH, Huang WH, et al: Bone marrow transplantation in Taiwan: an overview. Bone Marrow Transplant 1994;13:705-8.
23. Chen YC, Lin KH, Wang CH, et al: Allogeneic bone marrow transplantation in the treatment of leukemia: emphasis on graft-versus-host disease and veno-occlusive disease in a Taiwan population. Transplant Proc 1992:24: 1526-8.
24. Anderson JE, Anasetti C, Appelbaum FR, et al: Unrelated donor marrow transplantation for myelodysplasia (MDS) and MDS-related acute myeloid leukemia. Br J Haematol 1996;93:59-67.
25. Davies SM, Wagner JE, Defor T, et al: Unrelated donor bone marrow transplantation for children and adolescents with aplastic anemia or myelodysplasia. Br J Haematol 1997;96:749-56.
26. De Witte T, Biezen AV, Hermans J, et al: Autologous bone marrow transplantation for patients with myelodysplastic syndrome (MDS) or acute myeloid leukemia following MDS. Blood 1997;90:3853-7.
27. To LB, Haylock DN, Simmons PJ, et al: The biology and clinical use of blood stem cells. Blood 1997;89:2233-58.
28. Bensinger WI, Clift R, Martin P, et al: Allogeneic peripheral blood stem cell transplantation in patients with advanced hematologic malignancies: a retrospective comparison with marrow transplantation. Blood 1996:88:2794-800.
29. Schmitz N, Dreger P, Suttorp M, et al: Primary transplantation of allogeneic peripheral blood progenitor cells mobilized by filgrastim (granulocyte colony-stimulating factor). Blood 1995;85:1666-72.
30. Storek J, Gooley T, Siadak M, et al: Allogeneic peripheral blood stem cell transplantation may be associated with a high risk of chronic graft-versus-host disease. Blood 1997; 90:4705-9.
31. Przepiorka D, Anderlini P, Ippoliti C, et al: Allogeneic blood stem cell transplantation in advanced hematological cancers. Bone Marrow Transplant 1997;19:455-60.
32. Herzig RH, Coccia PF, Lazarus HM, et al: Bone marrow transplantation for acute leukemia and lymphoma with high-dose cytosine arabinoside and total body irradiation. Semin Oncol 1985;12(Suppl 3):184-6.
33. Riddel S, Appelbaum FR, Buckner CD, et al: High dose cytarabine and total body irradiation with or without cyclophosphamide as a preparative regimen for marrow transplantation for acute leukemia. J Clin Oncol 1988;6: 576-82.
34. Kumar M, Saleh A, Rao PV, et al: Toxicity associated with high-dose cytosine arabinoside and total body irradiation as conditioning for allogeneic bone marrow transplantation. Bone Marrow Transplant 1997;19:1061-4.
35. Anderson JE, Appelbaum FR, Schoch G, et al: Allogeneic marrow transplantation for myelodysplastic syndrome with advanced disease morphology: a phase II study of busulfan, cyclophosphamide, and total body irradiation and analysis of prognostic factors. J Clin Oncol 1996;4: 220-6.